Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHRA (Medicines and Healthcare products Regulatory Agency) issues POC (point of care) microalbuminuria test devices report:

This article was originally published in Clinica

Executive Summary

Point of care devices for the detection and semi-quantitation of microalbuminuria are the subject of the latest POC urine screening device evaluation report to be published by the UK Medicines and Healthcare products Regulatory Agency (MHRA). The report includes technical and user assessments of analytical performance, suitability for point of care and reliability. The devices evaluated are: Bayer Microalbumin read of the Bayer Clinitek Status urine strip reader, Bayer Microalbustix, Roche Diagnostics' [Chemstrip] Micral test and Diagnostic Chemicals' ImmunoDip urinary albumin.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel